Ionic liquid aerosols for respiratory complications related to COVID-19

Researchers in the lab of Samir Mitragotri have developed ionic liquid aerosols that have the potential to combat pulmonary bacterial infections. The technology may help to treat the respiratory conditions resulting from COVID-19 infection and reduce the burden on hospitals worldwide. Through industry-sponsored research, the team hopes to advance this technology toward commercialization.

Patients infected with the novel coronavirus virus can vary from asymptomatic to presenting with severe respiratory conditions that necessitate mechanical ventilation and support in intensive care units.To help tackle this issue, Prof. Mitragotri and his team are designing ionic liquids ( salts that exist in liquid phase at room temperature) that volatilize into aerosol formulations that can be inhaled into the lungs. The ionic liquids consist of GRAS substances and have demonstrated ability to kill a variety of pathogens including multi-drug-resistant mycobacteria, fungi, and viruses such as HPV.

Intellectual Property Status: Patent(s) Pending